{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:58:31Z","timestamp":1790492311524,"version":"4.1.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Support Program for Science and Technology of Sichuan Province","award":["2017SZ0106"],"award-info":[{"award-number":["2017SZ0106"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Myxofibrosarcoma (MFS) is a locally aggressive tumor and has the potential to be fatal because of distant metastasis. Immunotherapy targeting either programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently shown a curative effect on multiple cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma. Although the immunotherapy has been applied in sarcoma, there is little information about the efficiency to treat metastatic MFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 42-year-old male presented to the clinic with a mass in the left thigh. Mass resection and ligament replacement surgery were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was diagnosed as high-grade MFS (federation nationale des centres de lutte contre le cancer, Grade 3) with pulmonary metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>In the past few years, he was treated with surgery, chemoradiotherapy, and Anlotinib (an angiogenesis inhibitor), but the metastatic lesion continued to progress. About 40% to 50% of tumor cells in his pulmonary tissues were showed positive PD-L1 expression and his tumor mutational burden was 215Muts. Thus, he received Camrelizumab (PD-1 inhibitor).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Six months after the initiating immunotherapy of Camrelizumab, the size of pulmonary lesions showed marked shrinkage, indicating a partial response. After a follow-up of 18\u200amonths, the patient remained in good condition without progressive disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case described here demonstrated that immunotherapy of PD-1 inhibitor is a promising treatment option for refractory MFS with PD-L1 positive or tumor mutational burden -high, which could contribute to effective tumor response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000025262","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T15:40:03Z","timestamp":1616514003000},"page":"e25262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-220X","authenticated-orcid":false,"given":"Yi","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Xie","sequence":"additional","affiliation":[{"name":"Yinfeng Gene Technology Co Ltd, CORA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqi","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.soc.2016.05.008","article-title":"Myxofibrosarcoma","volume":"25","author":"Roland","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"8517371","DOI":"10.1155\/2019\/8517371","article-title":"High recurrence rate of myxofibrosarcoma: the effect of radiotherapy is not clear","volume":"2019","author":"Teurneau","year":"2019","journal-title":"Sarcoma"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.pas.0000213379.94547.e7","article-title":"Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases","volume":"31","author":"Nascimento","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.pathol.2017.05.003","article-title":"Pd-1 and Pd-L1 expression in bone and soft tissue sarcomas","volume":"49","author":"Torabi","year":"2017","journal-title":"Pathology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/cas.14148","article-title":"Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial","volume":"110","author":"Tamura","year":"2019","journal-title":"Cancer Sci"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"1811","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/03009734.2017.1356404","article-title":"Distant metastasis in patients with myxofibrosarcoma","volume":"122","author":"Tsuchie","year":"2017","journal-title":"Upsala J Med Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jjco\/hyw199","article-title":"A histological positive margin after surgery is correlated with high local re-recurrence rate in patients with recurrent myxofibrosarcoma","volume":"47","author":"Kikuta","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.athoracsur.2013.05.015","article-title":"Recurrence patterns after resection of soft tissue sarcomas of the chest wall","volume":"96","author":"McMillan","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"R10-20250504","first-page":"192","article-title":"Programmed death ligand 1 (PD-L1) expression in malignant mesenchymal tumors","volume":"33","author":"Kosemehmetoglu","year":"2017","journal-title":"Turk J Pathol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e1279777","DOI":"10.1080\/2162402X.2017.1279777","article-title":"PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma","volume":"6","author":"Budczies","year":"2017","journal-title":"Oncoimmunology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40792-019-0596-7","article-title":"Immunotherapy for advanced lung cancer combined with surgery for mediastinal myxofibrosarcoma: a case report","volume":"5","author":"Fukui","year":"2019","journal-title":"Surg Case Rep"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"221","DOI":"10.21873\/cgp.20127","article-title":"Pathogenic and targetable genetic alterations in resected recurrent undifferentiated pleomorphic sarcomas identified by targeted next-generation sequencing","volume":"16","author":"Zheng","year":"2019","journal-title":"Cancer Genom Proteom"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.4143\/crt.2017.529","article-title":"Pembrolizumab for refractory metastatic myxofibrosarcoma: a case report","volume":"50","author":"Song","year":"2018","journal-title":"Cancer Res Treat"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:27:14Z","timestamp":1746325634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025262"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025262","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"2020-12-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}